From: Enhanced immune complex formation in the lungs of patients with dermatomyositis
 | DM-ILD group | IPF group | P value |
---|---|---|---|
Number | 18 | 19 | Â |
Age | 54 (46–63) | 65 (62–67) | 0.001 |
Sex: male | 6 (33%) | 18 (95%) | 0.001 |
RP-ILD or IPF-AE | 9 (50%) | 9 (47%) | Â |
Tissue collection method | Â | Â | Â |
 SLB | 11 (61%) | 10 (53%) |  |
 Transplant | 1 (6%) | 0 (0%) |  |
 Autopsy | 6 (33%) | 9 (47%) |  |
Dx of IIMs | Â | Â | Â |
 DM | 12 (67%) | – |  |
 CADM | 6 (33%) | – |  |
Histological pattern | Â | Â | Â |
 DAD | 11 (61%) | 9 (47%) |  |
 NSIP | 6 (33%) | 0 (0%) |  |
 UIP | 1 (6%) | 10 (53%) |  |
Treatment for autopsy and lung transplant cases | Â | Â | Â |
 Corticosteroid | 7 (100%) | 8 (89%) |  |
 Calcineurin inhibitors | 6 (86%) | 2 (22%) |  |
 Cyclophosphamide | 5 (71%) | 3 (33%) |  |
Cause of death in autopsy cases | Â | Â | Â |
 Respiratory failure (including IPF-AE or RP-ILD) | 6 (100%) | 6 (67%) |  |
 Lung cancer | 0 (0%) | 3 (33%) |  |